BERGEM·HEALTH
Home Doctors Prof. Dr. Ali Murat Tatlı, MD
MEDICAL ONCOLOGY · MEMORIAL ANTALYA

Prof. Dr. Ali Murat Tatlı, MD

Professor of Medical Oncology · Memorial Antalya Hospital
Prof. Dr. Ali Murat Tatlı is a medical oncologist at Memorial Antalya Hospital. Trained at Istanbul University Faculty of Medicine (MD, 1992-1998), he completed internal medicine residency in Istanbul and his medical oncology sub-specialty at Akdeniz University. He served on the Akdeniz medical faculty before joining Memorial. He is a member of ESMO and the Turkish Medical Oncology Association, and Vice President of the Lung Cancer Working Group of the Turkish Lung Cancer Association.
Specialties: Oncology
25+
years in medicine
199
academic publications
ESMO
society member
ESMO MemberLung CancerBreast CancerNeuroendocrine TumorsClinical Research
A BergemHealth coordinator arranges contact with the professor within 24–48 hours on business days.
Direct contract with BergemHealth
CONSULTATION LANGUAGES
TR Turkish · native
EN English · professional
RU Russian · via BergemHealth coordinator
UK Ukrainian · via BergemHealth coordinator
ANTALYA · 06/2026
EDUCATION & CAREER

Timeline

Career milestones.

2007-2009
Internal Medicine Specialist
Gaziantep Şehit Kamil State Hospital
2012-recent
Faculty member / Medical Oncologist
Akdeniz University Faculty of Medicine, Antalya
recent-present
Medical Oncologist
Memorial Antalya Hospital
PUBLICATIONS

Scientific work

Selected peer-reviewed publications.

  • 2012
    Med Oncol
    «Primary mucinous adenocarcinoma of the bladder: complete response with FOLFOX-4 regimen»
    · first author · 19 citations
  • 2020
    J Cancer
    «A retrospective evaluation of geriatric patients with gastric cancer receiving systemic chemotherapy»
    · first author · 7 citations
  • 2015
    J Cancer
    «Retrospective analysis of third-line chemotherapy in advanced non-small cell lung cancer»
    · first author · 7 citations
  • 2024
    World J Gastric Cancer
    «Prognostic significance of tumor budding, desmoplastic reaction, and lymphocytic infiltration in patients with gastric adenocarcinoma»
    · co-author · 6 citations
  • 2014
    J BUON
    «Treatment with capecitabine + bevacizumab following induction treatment with FOLFIRI + bevacizumab in metastatic colorectal carcinoma»
    · first author · 2 citations
  • 2023
    J Cancer Res Clin Oncol
    «Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations»
    · co-author · 3 citations
REQUEST

Tell me about your case — I’ll read it personally.

Fill in the short form on the consultation page — diagnosis, preferred timing, attached records. We assemble a tumour board for your case and reply within 4 hours.

Open the consultation form
  • Reply within 4 hours during business hours
  • Confidentiality guaranteed
  • Coordinator-translator inside the doctor’s office
  • Tumour board of 2–3 professors within 72 hours